Abstract
Abstract IL-6 is a multifunctional cytokine that has been involved in modulation of growth and differentiation in several malignant tumors. Studies have shown its role as an important autocrine growth factor for androgen-dependent human prostate cancer in vivo. Serum IL-6 has also been associated with poor prognosis in prostate cancer. We performed a digital analysis of IL-6 immunoreactivity in prostate cancer epithelial cells to determine differences in IL-6 expression between recurrence and non-recurrence groups in a PCa nested case-control cohort. We analyzed an outcome-based TMA obtained from the Cooperative Prostate Cancer Tissue Resource (CPCTR) containing quadruplicate cores (0.6mm core diameter) from 200 pairs of PCa tumor samples (n=400). Cases with PSA recurrence were matched 1:1 with cases without recurrence by race, age, year of surgery, Gleason grade, and pathological stage. All cases had at least five-years follow up. TMA slides were incubated with rabbit polyclonal IL-6 antibody (Abcam) in a 1:600 dilution. Expression levels of IL-6 were assessed by Colocalization Algorithm (ScanScope®, Aperio Corp). Differences in IL-6 intensity between case-control pairs were calculated by Wilcoxon signed rank paired test. Automated data was available for analysis in 149 pairs (n=298). The Wilcoxon signed rank test showed no statistically significant differences in IL-6 intensity between the two groups (p = 0.7). To the best of our knowledge, this is the first study to examine the expression of IL-6 in a large PCa TMA set. Our results revealed IL-6 expression in cancer tissue; however, after statistical analysis, no significant differences were obtained to indicate that IL-6 may be considered as prognostic marker of prostate cancer with biochemical recurrence if cases were first matched by race, age, date of prostatectomy, Gleason score, and stage. In our study we excluded stromal and inflammatory cells IL-6 expression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1756.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
